Search / Trial NCT00000371

Trial of D-Cycloserine in Schizophrenia

Launched by MASSACHUSETTS GENERAL HOSPITAL · Nov 2, 1999

Apply for Trial

Trial Information

Current as of March 05, 2024

Completed

Keywords

Adult Cognition Cycloserine Dopamine Female Glutamic Acid Human Male Receptors, N Methyl D Aspartate Schizophrenia Serotonin Quality Of Life Cycloserine *Therapeutic Use Dopamine Blood Dopamine Cerebrospinal Fluid Glutamic Acid Blood Glutamic Acid Cerebrospinal Fluid Serotonin Blood Serotonin Cerebrospinal Fluid

Description

To characterize further the effects of D-cycloserine augmentation of antipsychotic treatment on negative symptoms, performance on neurocognitive tasks, and on markers for glutamatergic, dopaminergic, and serotonergic function in serum and cerebrospinal fluid. To determine if negative symptoms and cognitive function improve over time, if these improvements meaningfully impact quality of life factors, if they correlate with markers of neuronal function, and if subpopulations can be identified according to response. Dysfunction of glutamatergic neuronal systems has recently been implicated in...

Gender

All

Eligibility criteria

  • Inclusion Criteria:
  • Diagnosis of Schizophrenia as per DSM IV criteria
  • Have been treated for at least 6 months with any conventional neuroleptic
  • Have prominent negative symptoms as defined by a total score of 40 or greater on the scale for the assessment of negative symptoms (SANS)
  • Exclusion Criteria:
  • Active alcohol or drug abuse
  • Unstable Medical Illness, seizure disorder, or other serious neurological disorder
  • Pregnant or Nursing
  • Unable to complete a cognitive battery

Attachments

readout_NCT00000371_2024-03-05.pdf

4.5 MB

NCT00000371_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Baseline, Week 4, Week 8

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0